SIQ17, an EGFR inhibitor, blocks the ATP-binding site with an IC50 of 0.62 nM, demonstrating more effective EGFR-TK inhibitory activity than the known inhibitor Erlotinib (IC50 of ∼20 nM). SIQ17 is applicable in cancer research [1].

SIQ17 demonstrates a stronger inhibitory effect on the viability of A431 cells compared to A549 cells at a concentration of 10 μM over 72 hours [1]. This compound exhibits cytotoxic effects in a concentration-dependent manner, with IC50 values of 32.98 μM for A549 cells and 19.17 μM for A431 cells after 24 hours of exposure [1]. Furthermore, cell viability assays conducted at 10 μM for 72 hours confirm the greater inhibition on A431 cells relative to A549. Additionally, cytotoxicity assays involving A549, A431, and Vero cell lines at concentrations ranging from 0-100 μM over 24 hours consistently show the compound's cytotoxic nature, with specific IC50 values reported as 32.98 μM and 19.17 μM for A549 and A431, respectively [1].